Healthspan Economy
Diagnostics & Assessment · M-36

Continuous glucose monitoring

Limited evidence 6 in the Atlas
In brief

Continuous glucose monitoring (CGM) uses a wearable sensor and phone app to record glucose around the clock. It is standard in insulin-treated diabetes. The FDA cleared the first over-the-counter CGM in March 2024 for adults who do not use insulin, with up to 15 days of wear. Longevity clinics apply it for a set period to show how meals, sleep and exercise move glucose. Studies in healthy adults describe normal glucose patterns and do not show that acting on readings improves health. Evidence tier: limited.

What it is

A continuous glucose monitor (CGM) is a small sensor worn on the skin, often on the back of the arm, that measures glucose in the fluid under the skin every few minutes and sends the readings to a phone app. It was built for people with diabetes, where it guides insulin and medication decisions. In March 2024 the FDA cleared the first over-the-counter version for adults who do not use insulin, including people without diabetes. Longevity clinics apply it for a set period, sometimes two weeks, to show how meals, sleep, exercise and stress move a person's glucose. The evidence for healthy adults mainly describes what normal glucose looks like, as in a 2019 study of 153 people, rather than showing that acting on the readings improves health.

Who it is for

CGM is established care for people with diabetes who use insulin, where it guides dosing. For adults without diabetes the FDA clearance of the first over-the-counter version in March 2024 covers anyone 18 or older who does not use insulin, including people who want to see how diet and exercise affect their glucose. The FDA's clearance notice says such users should not make medical decisions from the output without talking to a health care provider, and that the device is not for people with problematic hypoglycemia. Whether acting on the readings improves health in people without diabetes is not shown by the studies cited here.

What to expect

A sensor is applied to the skin, often the back of the upper arm, and a phone app shows readings and trends. The cleared over-the-counter sensor, the Dexcom Stelo, is worn for up to 15 days before replacement. Longevity clinics apply it for a set period, sometimes two weeks, and where a program includes review, someone compares the readings against meals, sleep, exercise and stress.

History and background

CGM was developed for diabetes care, and the American Diabetes Association's Standards of Care treats it in its diabetes technology chapter, the 2026 edition of which is cited here. On March 5, 2024 the FDA cleared the Dexcom Stelo as the first over-the-counter CGM, for adults who do not use insulin. That clearance moved the sensor from prescription diabetes care to consumer and longevity use.

Worth knowing

The FDA described the 2024 clearance as the first over-the-counter CGM. The device shows readings and trends every 15 minutes. A 2019 multicenter prospective study in the Journal of Clinical Endocrinology and Metabolism, of healthy people without diabetes, described what normal glucose profiles look like, which is the kind of evidence available for healthy adults.

Offered across the Atlas 6

Related modalities

Limited evidence: Mechanistically plausible; human outcome data is thin.